Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
ChemoCentrix Spikes 110% on Amgen Acquisition Deal
06:10pm, Thursday, 04'th Aug 2022
On Thursday, shares of ChemoCentryx Inc. ( CCXI , Financial) shot up more than 110% before closing the day at $50.43 on the news that the small-cap biotech company has entered into an agreement to be
SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc
04:45pm, Thursday, 04'th Aug 2022
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ChemoCentryx, Inc. Buyout
03:21pm, Thursday, 04'th Aug 2022
Wilmington, Delaware--(Newsfile Corp. - August 4, 2022) - Rigrodsky Law, P.A. is investigating ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) regarding possible breaches of fiduciary duties and ot
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
12:18pm, Thursday, 04'th Aug 2022
Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why Is It Moving?
ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition
11:30am, Thursday, 04'th Aug 2022
Source: Shutterstock ChemoCentryx (NASDAQ: CCXI ) stock is rocketing higher on Thursday as investors react to news of an acquisition deal with Amgen (NASDAQ: AMGN ). This deal has Amgen agreeing to ac
Shareholder Alert: Ademi LLP investigates whether ChemoCentryx, Inc. has obtained a Fair Price in its transaction with Amgen
11:18am, Thursday, 04'th Aug 2022
MILWAUKEE , Aug. 4, 2022 /PRNewswire/ -- Ademi LLP is investigating ChemoCentryx (NASDAQ: CCXI) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen. Cl
Why Amgen (AMGN) Is Buying ChemoCentryx (CCXI) For $4 Billion In Cash
10:39am, Thursday, 04'th Aug 2022
Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details.
Why ChemoCentryx Stock Is On Fire Today
10:08am, Thursday, 04'th Aug 2022
The rare-disease specialist is being bought out at a sizable premium.
Amgen to gain rare-disease drug in $3.7 billion acquisition of ChemoCentryx
08:24am, Thursday, 04'th Aug 2022
Amgen Inc. AMGN, +1.32% said Thursday it plans to buy ChemoCentryx Inc. CCXI, +3.61% for $3.7 billion in cash. The deal will give Amgen access to Tavneos, a treatment for ANCA-associated vasculitis th
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
04:05pm, Tuesday, 02'nd Aug 2022
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close o
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
01:59pm, Tuesday, 05'th Jul 2022
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
08:30am, Monday, 16'th May 2022
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. W
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the p
ChemoCentryx: A Biotech Stock Well Worth the Risk
04:00am, Monday, 09'th May 2022
In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point for a stock that had been in a
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
05:18pm, Friday, 06'th May 2022
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
